Digital twins have emerged as a groundbreaking technology in healthcare, offering the potential to simulate and predict individualized treatment responses for complex diseases like multiple sclerosis (MS). At their core, digital twins are highly detailed, computer-generated models that replicate the…
Patient-reported outcomes have become a crucial tool in capturing the invisible symptoms of multiple sclerosis (MS), a chronic and often debilitating neurological condition. MS is characterized by a wide range of symptoms, many of which are not immediately visible to…
When considering pragmatic trial designs for rapidly evolving multiple sclerosis (MS) therapeutics, the key challenge is to balance scientific rigor with real-world applicability and flexibility. MS is a complex, heterogeneous disease with multiple subtypes and variable progression rates, and new…
## Can EHR-Derived Endpoints Reliably Measure MS Disability Progression? Multiple sclerosis (MS) is a complex, chronic disease that affects the central nervous system, leading to a wide range of symptoms and disability over time. Tracking how MS progresses is crucial…
## Understanding Multiple Sclerosis Research: The Roles of Randomized Trials and Real-World Registries Multiple sclerosis (MS) is a complex, lifelong neurological disease that affects millions worldwide. To understand which treatments work best and for whom, researchers rely on two main…
Progressive multifocal leukoencephalopathy (PML) is a rare but serious brain infection caused by the JC virus (JCV), which typically remains dormant in most people but can reactivate in those with weakened immune systems. In multiple sclerosis (MS) care, certain immunomodulatory…
## Understanding the Burden of Opportunistic Infections with Natalizumab and S1P Modulators When people with multiple sclerosis (MS) start treatments like natalizumab or S1P modulators, their doctors often talk about something called “opportunistic infections.” These are infections that usually don’t…
When considering antiviral prophylaxis strategies in patients with multiple sclerosis (MS) who are profoundly B-cell-depleted, it’s essential to understand the complex interplay between the immune system, antiviral treatments, and the underlying condition of MS. MS is an autoimmune disease where…
The relationship between COVID-19 infection, COVID-19 vaccination, and the risk of relapse in people with Multiple Sclerosis (MS) is a topic of significant interest and concern. MS is a chronic neurological condition characterized by episodes of new or worsening symptoms…
Optimizing vaccination schedules for patients on anti-CD20 therapy requires careful timing and consideration of the therapy’s impact on the immune system, particularly B-cell depletion. Anti-CD20 therapies, such as rituximab, target B cells, which are crucial for producing antibodies in response…